Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biology | 1 | 2022 | 6 | 0.750 |
Why?
|
| Phosphoproteins | 1 | 2022 | 7 | 0.750 |
Why?
|
| Databases, Factual | 2 | 2019 | 54 | 0.610 |
Why?
|
| Thoracic Surgery | 1 | 2019 | 1 | 0.590 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2019 | 1 | 0.590 |
Why?
|
| Quality Improvement | 1 | 2019 | 34 | 0.570 |
Why?
|
| Pneumonectomy | 2 | 2015 | 7 | 0.550 |
Why?
|
| Mucormycosis | 1 | 2015 | 2 | 0.450 |
Why?
|
| Lung Diseases, Fungal | 1 | 2015 | 3 | 0.440 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 6 | 0.440 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 87 | 0.400 |
Why?
|
| Humans | 11 | 2022 | 5837 | 0.320 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2010 | 3 | 0.310 |
Why?
|
| Energy Intake | 1 | 2010 | 36 | 0.310 |
Why?
|
| Enteral Nutrition | 1 | 2010 | 16 | 0.310 |
Why?
|
| Critical Care | 1 | 2010 | 25 | 0.300 |
Why?
|
| Biomarkers, Tumor | 3 | 2014 | 37 | 0.230 |
Why?
|
| Adult | 7 | 2017 | 1670 | 0.220 |
Why?
|
| Male | 9 | 2019 | 3399 | 0.220 |
Why?
|
| Adenocarcinoma | 3 | 2017 | 27 | 0.210 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 63 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 29 | 0.180 |
Why?
|
| Aged | 6 | 2019 | 1860 | 0.150 |
Why?
|
| Middle Aged | 6 | 2017 | 1775 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 5 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2019 | 14 | 0.150 |
Why?
|
| Societies, Medical | 1 | 2019 | 21 | 0.150 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 1034 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 10 | 0.150 |
Why?
|
| Female | 7 | 2019 | 3346 | 0.140 |
Why?
|
| Lymphoma | 1 | 2017 | 8 | 0.130 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 4 | 0.130 |
Why?
|
| Carcinoma | 1 | 2017 | 11 | 0.130 |
Why?
|
| Melanoma | 1 | 2017 | 16 | 0.130 |
Why?
|
| Biopsy | 1 | 2017 | 37 | 0.130 |
Why?
|
| Sarcoma | 1 | 2017 | 19 | 0.130 |
Why?
|
| Bronchi | 1 | 2015 | 2 | 0.110 |
Why?
|
| Surgical Flaps | 1 | 2015 | 9 | 0.110 |
Why?
|
| Thymus Gland | 1 | 2015 | 8 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 11 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 5 | 0.110 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 7 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 25 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 37 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2017 | 584 | 0.090 |
Why?
|
| Lung Transplantation | 1 | 2011 | 2 | 0.080 |
Why?
|
| Living Donors | 1 | 2011 | 2 | 0.080 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2011 | 7 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2011 | 13 | 0.080 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 12 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2010 | 1 | 0.080 |
Why?
|
| Surgical Tape | 1 | 2010 | 1 | 0.080 |
Why?
|
| Glasgow Coma Scale | 1 | 2010 | 2 | 0.080 |
Why?
|
| APACHE | 1 | 2010 | 7 | 0.080 |
Why?
|
| Conscious Sedation | 1 | 2010 | 3 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 1 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2008 | 11 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2008 | 21 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2008 | 21 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 51 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 74 | 0.060 |
Why?
|
| Young Adult | 2 | 2017 | 421 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 125 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 333 | 0.040 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Thoracoscopy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2019 | 14 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 25 | 0.040 |
Why?
|
| Pneumonia | 1 | 2019 | 25 | 0.040 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 2 | 0.030 |
Why?
|
| Tonsillar Neoplasms | 1 | 2017 | 2 | 0.030 |
Why?
|
| Carcinoma, Embryonal | 1 | 2017 | 2 | 0.030 |
Why?
|
| Thymoma | 1 | 2017 | 3 | 0.030 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 3 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 10 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 11 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 19 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 21 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 69 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 5 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 19 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 34 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 53 | 0.030 |
Why?
|
| Illinois | 1 | 2014 | 52 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 63 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 100 | 0.030 |
Why?
|
| Prognosis | 1 | 2014 | 138 | 0.030 |
Why?
|
| Algorithms | 1 | 2014 | 82 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 157 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 163 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 150 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2011 | 3 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 21 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2011 | 30 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 406 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 1 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2008 | 2 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 2 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 2 | 0.020 |
Why?
|
| Adipokines | 1 | 2008 | 2 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 4 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 18 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 31 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 37 | 0.020 |
Why?
|
| Azacitidine | 1 | 2008 | 7 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2011 | 601 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 32 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 34 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 60 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 87 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 136 | 0.020 |
Why?
|